LearnGlossaryMarketStocksSuperinvestorsSign in

ANIX

Anixa Biosciences, Inc.

Healthcare · $93M market cap

Verdict

We can't put a fair value on ANIX right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth4.1% a year✗
Sales growth-5.3% a year✗
Free cash flow growth—?
Return on invested capital-67.3%✗

Follow ANIX

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 10, 2026: 1 open-market purchase worth $14K. Why purchases matter

Purchases

KUMAR AMIT

Chief Executive Officer · 2026-09-10

Bought

$14K

About Anixa Biosciences, Inc.

Anixa Biosciences, Inc. (ANIX) is a biotechnology company dedicated to pioneering therapies and vaccines. Its core mission revolves around addressing critical, unmet medical needs, particularly within the fields of oncology (cancer) and infectious diseases. Among its therapeutic pipeline, Anixa is developing a novel chimeric endocrine receptor T-cell (CER-T) technology, an innovative adaptation of CAR-T…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works